Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

The present disclosure provides methods related to treating triple-negative breast cancer (TNBC) in a mammal by administering salvianolic acid B (or a salt or solvate thereof) to promote ceramide-mediated apoptosis. In one form, the ceramide-mediated apoptosis of TNBC cells occurs by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in the subject through the use of an effective amount of salvianolic acid B. In another aspect, salvianolic acid B or its pharmaceutically acceptable salt or solvate is used as a medicament or in the manufacture of a medicament for treating TNBC.

Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.

Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.

Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.

Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.

Compounds of the formulae (I) or (II) ##STR00001##
wherein X is ##STR00002## A is O, S, NR.sub.5 or CR.sub.16R.sub.17; R.sub.1 is for example hydrogen or C.sub.1-C.sub.20alkyl R.sub.2 is for example hydrogen, C.sub.1-C.sub.20alkyl or C.sub.6-C.sub.20aryl R.sub.5 for example is C.sub.1-C.sub.20alkyl; R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 for example independently of each other are hydrogen. C.sub.1-C.sub.20alkyl, halogen, CN or NO.sub.2; Ar.sub.1 is for example unsubstituted or substituted C.sub.6-C.sub.20aryl, C.sub.3-C.sub.20heteroaryl, C.sub.6-C.sub.20aroyl, C.sub.3-C.sub.20heteroarylcarbonyl or ##STR00003## or Ar.sub.1 is ##STR00004## Ar.sub.2 is for example phenylene, ##STR00005##
all of which are unsubstituted or substituted M is for example unsubstituted or substituted C.sub.1-C.sub.20alkylene Y is a direct bond, O, S, NR.sub.5 or CO; Z.sub.1 is for example O or S; Z.sub.2 is a direct bond, O, S or NR.sub.5; and Q is CO or a direct bond.

Compounds of the formulae (I) or (II) ##STR00001##
wherein X is ##STR00002## A is O, S, NR.sub.5 or CR.sub.16R.sub.17; R.sub.1 is for example hydrogen or C.sub.1-C.sub.20alkyl R.sub.2 is for example hydrogen, C.sub.1-C.sub.20alkyl or C.sub.6-C.sub.20aryl R.sub.5 for example is C.sub.1-C.sub.20alkyl; R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 for example independently of each other are hydrogen. C.sub.1-C.sub.20alkyl, halogen, CN or NO.sub.2; Ar.sub.1 is for example unsubstituted or substituted C.sub.6-C.sub.20aryl, C.sub.3-C.sub.20heteroaryl, C.sub.6-C.sub.20aroyl, C.sub.3-C.sub.20heteroarylcarbonyl or ##STR00003## or Ar.sub.1 is ##STR00004## Ar.sub.2 is for example phenylene, ##STR00005##
all of which are unsubstituted or substituted M is for example unsubstituted or substituted C.sub.1-C.sub.20alkylene Y is a direct bond, O, S, NR.sub.5 or CO; Z.sub.1 is for example O or S; Z.sub.2 is a direct bond, O, S or NR.sub.5; and Q is CO or a direct bond.

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.